Close Menu

Proteomics International Promarker D

Mar 20, 2018

Proteomics International Laboratories' partner Omics Global Solutions launched PromarkerD, a predictive diagnostic test for diabetic kidney disease. The test was launched through OMG's distributor in the Dominican Republic, Macrotech Farmaceutica. Proteomics International is in discussions with potential partners to bring the test to the US, Mexico, Japan, Australia, China, and Europe. The test is a mass spec-based laboratory-developed test, Proteomics International said, adding it anticipates another licensing deal for the test with a certified lab in coming weeks. The firm plans on developing an in vitro diagnostic immunoassay version of Promarker D for use in clinical labs. 

More Like This

Mar 19, 2019

Asuragen AmplideX PCR/CESMN1/2 Kit

Asuragen has launched the AmplideX PCR/CE SMN1/2 kit. Building upon the testing workflow of the AmplideX PCR/CE SMN1 Kit, the new assay quantifies both SMN1 and SMN2 exon 7 copy number in less than four hours from a single PCR reaction. The assay shares a common testing workflow with all other assays in the AmplideX portfolio and is similarly optimized for use on broadly installed Thermo Fisher Scientific Applied Biosystems Genetic Analyzers. Interest in SMN1 and SMN2 copy number quantification has grown following the 2016 FDA approval of nusinersen (Biogen Idec's Spinraza) for the treatment of spinal muscular atrophy, a disease attributable to loss of functional copies of the SMN1 gene, and the severity of which is inversely correlated with the number of copies of SMN2, Asuragen noted.

Mar 19, 2019

Strata Oncology StrataNGS

Strata Oncology has launched version 3.0 of StrataNGS, its pan-cancer assay for solid tumors. The updated 500-gene assay sequences DNA and RNA from tumor samples to detect all clinically actionable biomarkers — including microsatellite instability, tumor mutational burden, and PD-L1 — recommended by leading guidelines, in a single test. Test results are provided in a streamlined report that facilitates interpretation and identification of potential treatment options and clinical trials, Strata said.

Mar 19, 2019

Mission Bio Tapestri Designer

Mission Bio has launched Tapestri Designer, a cloud-based tool for customers to design and order single-cell DNA panels. The tool makes use of artificial intelligence and machine learning to enable customers to order customized gene panels, reducing turnaround time for panel design to minutes from weeks, according to the company. Tapestri Designer allows researchers to complete custom designs in three steps: set up an account; upload a CSV file or enter a gene, ID, or coordinate targets; and submit a design to receive results.

Mar 18, 2019

Karolinska University Hospital Genetic Analysis Services

The Mutation Analysis Facility (MAF) at Karolinska University Hospital is launching a range of genetic analysis services targeting the European research and clinical market and focusing on areas such as cancer profiling for solid tumors and liquid biopsy, as well as pharmacogenetics. MAF has ISO/IEC 17025 accreditation for core methods by the Swedish SWEDAC authority, and will offer a broad portfolio of services including genome-wide analysis, targeted epigenetic analysis, and DNA methylation for precision medicine research and clinical decision making. Karolinska highlighted in particular its SNP genotyping expertise, noting that it uses MALDI-TOF analysis performed on Agena Bioscience's MassArray platform to simultaneously genotype several SNPs for both small- and large-scale applications.

Mar 14, 2019

Shield Diagnostics Target-NG

Shield Diagnostics, a CLIA-certified clinical laboratory based in San Jose, California, has launched Target-NG, a rapid molecular test for antibiotic susceptibility in Neisseria gonorrhoeae. The test, which users can run on urine, rectal, and pharyngeal samples, can determine if a given gonorrhea infection is susceptible to ciprofloxacin with the same turnaround time as standard gonorrhea screening tests, the company said.

Mar 12, 2019

Diagenode Megaruptor 3

Diagenode has launched Megaruptor 3, a new version of its DNA shearing instrument. The Megaruptor pumps DNA in solution through an array of uniform pores several times, stretching and breaking the DNA strands in the process. The device is designed to shear DNA into 5 kb to 100 kb fragments and can handle between one and eight samples per run.

Mar 12, 2019

Integrated DNA Technologies and Aldevron's GMP SpyFi Cas9 Nuclease

Aldevron and Integrated DNA Technologies have released GMP SpyFi Cas9 Nuclease for clinical and commercial applications. SpyFi Cas9 Nuclease, which is the trade name for Aldevron's research grade and GMP products, was developed through a partnership between the two companies. The advantages of SpyFi Cas9 Nuclease include reduced off-target effects combined with clinically relevant on-target activity, Aldevron said. Its release provides researchers and scientists with a consistent product for gene editing programs, from discovery through clinical and commercial manufacturing. 

This specific Cas9 protein variant resulted from a substantial amount of development of the wild-type Streptococcus pyogenes Cas9 sequence. This nuclease also functions well in ribonucleoprotein (RNP) delivery format and is compatible with ex vivo gene editing protocols. GMP-grade SpyFi Cas9 Nuclease is available in 1 mg and 10 mg vials.

Mar 12, 2019

Oxford Nanopore Technologies Flongle

Oxford Nanopore Technologies has launched Flongle ("flow cell dongle"), an adapter for the MinIon and GridIon X5 sequencing platforms that takes single-use flow cells. Each $90 Flongle flow cell contains 126 channels and currently produces up to 1.8 Gb of sequence data, an output that is expected to increase to more than 3 Gb in the future. The firm said it has designed the device for small-genome sequencing, panel sequencing, metagenomic sequencing to identify microbes or characterize microbiomes, and library quality control for larger nanopore sequencing experiments.

Mar 11, 2019

DNAnexus Clinico-Genomic Cohort Browser

DNAnexus has added a cohort browser to its DNAnexus Apollo platform for clinico-genomic data science exploration, analysis, and discovery. This represents the commercial launch of a browser that the Regeneron Genetics Center used to analyze a new set of 50,000 exomes and related phenotypes for the UK Biobank study.

Mar 11, 2019

23andMe Type 2 Diabetes Report

Consumer genetics company 23andMe on Sunday launched a Type 2 Diabetes Report that tells customers if they are at risk of developing the disease and the lifestyle changes that could make a positive difference. "The report can help customers learn how their genetics, along with other factors such as their weight, age and lifestyle, may influence the likelihood of developing type 2 diabetes, as well as actions they can take to lower that likelihood," 23andMe said in a blog post.

Unlike the company's other genetic health risk tests, which tell customers if they have specific disease-linked SNPs, the type 2 diabetes test employs a polygenic risk score (PRS) that combines more than 1,000 SNPs in an algorithm. This latest test has not been approved or cleared by the US Food and Drug Administration in contrast to the firm's earlier genetic health risk tests.

23andMe said it developed and validated the PRS using the real-world data of 2.5 million customers who have opted to donate their genetic and phenotypic information to research. In a white paper, the company notes that the type 2 diabetes PRS was developed on variants from genome-wide association studies involving people of European ancestry, and that it trained the score on Europeans and recalibrated for other populations. The data show that the score works best in those of European ancestry and doesn't work as well in African American populations.

Mar 07, 2019

LGC, Biosearch Technologies RapiDxFire Thermostable RT

LGC, Biosearch Technologies has launched RapidDxFire Thermostable RT, a thermostable reverse transcriptase designed specifically for diagnostic kit developers. The enzyme's optimum temperature of 55° C to 80° C improves reaction specificity and allows synthesis from diverse RNA templates. It also has a reaction time of five minutes or less, and is recommended for targets under 1 kb. Its extended stability at room temperature make it compatible with automation, and the enzyme is available in a lyophilization-ready Triton X-100-free format, the company said.

Mar 07, 2019

BioIVT Xpressway Profile Safety Package

BioIVT has launched the Xpressway Profile Safety Package, a compendium of 46 expression profiles for genes known to play pivotal roles in drug safety assessments. These genes are included in the initial screening panel used by pharmaceutical companies to evaluate new chemical entities for potential off-target interactions and toxic effects. Once these entities have been screened against the 46 target genes, the Xpressway Profile Safety Package allows the resulting binding data to be compared with the corresponding human target expression profiles and interpreted further to assess potential safety risk, the company said. When NCEs bind to the targets, the tissue distribution of those targets can inform decision making about the compounds and chemical series. BioIVT said that it employed a rigorous, highly controlled qRT-PCR method to develop the Xpressway Profile Safety Package's gene expression data.

Mar 06, 2019

IDT rhAmpSeq Targeted Sequencing System

Integrated DNA Technologies (IDT) has launched the rhAmpSeq targeted sequencing system. The proprietary rhAmpSeq chemistry enables highly multiplexed target amplification for sequencing on Illumina platforms with high on-target rates and uniform coverage. Its applications include human disease research, sample tracking and analysis, CRISPR genome editing analysis, and agricultural biotechnology. The system makes use of IDT's RNase H2 PCR technology, employing an RNase H2/DNA polymerase enzyme system coupled with RNA-DNA hybrid primers. It has been optimized for panel sizes from tens to thousands of amplicons in a single reaction.

Mar 06, 2019

Beckman Coulter Apostle Minimax High Efficiency Cell-Free DNA Isolation Kit

Beckman Coulter has launched the Apostle MiniMax High Efficiency Cell-Free DNA Isolation Kit through an exclusive partnership with liquid biopsy firm Apostle. The tool is a magnetic nanoparticle-based kit that extracts cfDNA from plasma using manual or automated workflows. According to the firm, the kit performs reliably across a range of volume inputs while consistently recovering high quantities of cfDNA and effectively removing contaminants. 

Mar 05, 2019

Loop Genomics mRNA Transcript Counting and Phasing

Loop Genomics has launched a kit and service for mRNA transcript counting and phasing using its synthetic long-read technology that works in conjunction with next-generation sequencing on Illumina instruments. The kit costs $70 per sample and the service $299 per sample. The San Jose, California-based startup, uses unique molecular identifiers and enzymes to attach the same barcode at multiple positions along one long molecule.

Matt Hancock, the UK health secretary, is calling for the swift rollout of predictive genetic tests, the Guardian reports.

A WHO panel is calling for a global registry of human germline gene-editing projects, according to Stat News.

Vox writes that lab mishaps involving pathogens are quite common.

In Genome Biology this week: analysis of wild and cultivated peach genomes, Hi-C-based pipeline for assembling microbial genomes from metagenomic data, and more.

Apr
30
Sponsored by
Lexogen

This webinar will discuss novel long-read transcript sequencing (LRTseq) methods for transcriptome annotation that could increase the efficiency and accuracy of future sequencing projects.